The proactivity, pace and dynamism of this sector is encouraging companies to pursue fundamentally different operational and business models. Large healthcare organisations are transforming themselves to capitalise on new scientific breakthroughs that make biologics a major growth opportunity, through restructuring and acquisition. 

Biotech leaders are revising their strategy to become attractive acquisition targets. We connect them with the key figures we know across the industry – the scientific experts, corporate leaders and board members with access to the right market contacts.

Through our work with private equity investors we have a firm-wide understanding of the nature of start-ups, the pressures of funding and how this relates to scientific developments. We assess teams in biotech for potential acquisition and investment, leveraging our knowledge of specialised roles that has made us part of the evolution of the industry.

We engage regularly with cross-functional teams and cross-divisional leaders, through whom we gain early insight into the evolving, inter-disciplinary nature of medical progress. Our global team helps clients to understand emerging leaders, mobility & immigration, research funding and remuneration, leveraging search and assessment to achieve the right commercial outcomes.